financetom
Business
financetom
/
Business
/
VF Fiscal Q1 Adjusted Loss Widens, Revenue Declines; Shares Rise After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
VF Fiscal Q1 Adjusted Loss Widens, Revenue Declines; Shares Rise After Hours
Aug 6, 2024 2:44 PM

05:16 PM EDT, 08/06/2024 (MT Newswires) -- VF (VFC) reported a fiscal Q1 adjusted loss late Tuesday of $0.33 per share, widening from the loss $0.15 a year earlier.

Analysts surveyed by Capital IQ expected a loss of $0.37.

Revenue in the quarter ended June 30 fell to $1.91 billion from $2.09 billion a year earlier.

Analysts surveyed by Capital IQ expected $1.85 billion.

The company maintained a quarterly dividend of $0.09 a share, payable Sept. 18 to shareholders of record Sept. 10.

Shares of the company rose 5.2% in recent after-hours activity.

Price: 17.30, Change: +0.86, Percent Change: +5.23

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Italy's Marcolin to produce, distribute Abercrombie & Fitch glasses from 2025
Italy's Marcolin to produce, distribute Abercrombie & Fitch glasses from 2025
Sep 16, 2024
MILAN, Sept 16 (Reuters) - Italian eyewear maker Marcolin signed an exclusive multi-year licensing agreement with Abercrombie & Fitch ( ANF ) to produce and distribute sunglasses and optical frames for the US fashion retailer, the two companies said in a joint statement on Monday. Spring and summer collections - for the Abercrombie, abercrombie Kids and Hollister brands - will...
Merck Says Keytruda Combination Improved Overall Survival for Breast Cancer Patients in Phase 3 Trial
Merck Says Keytruda Combination Improved Overall Survival for Breast Cancer Patients in Phase 3 Trial
Sep 16, 2024
04:18 AM EDT, 09/16/2024 (MT Newswires) -- Merck ( MRK ) said Sunday a phase 3 trial of Keytruda in combination with chemotherapy before surgery and after surgery without chemotherapy showed improved overall survival rates in patients with high-risk early-stage triple-negative breast cancer. Among the 1,174 patients enrolled in the study, the patients treated with the Keytruda combination showed an...
Italian private bank Banca Generali bids for broker Intermonte
Italian private bank Banca Generali bids for broker Intermonte
Sep 16, 2024
MILAN (Reuters) -Italian private bank Banca Generali on Monday said it was launching a 98 million euro ($109 mln) all-cash buyout bid for Intermonte, to take the Milanese broker private and direct its services at Banca Generali clients. Shares in Intermonte failed to start trading at the market open, and were last indicated up 19.6%, broadly in line with the...
Replimune Group Says Potential Melanoma Treatment Study Yielded Positive Results
Replimune Group Says Potential Melanoma Treatment Study Yielded Positive Results
Sep 16, 2024
04:39 AM EDT, 09/16/2024 (MT Newswires) -- Replimune Group ( REPL ) said Sunday that an analysis of a trial of its drug RP1 combined with nivolumab showed clinically meaningful and durable systemic anti-tumor activity in patients with anti-PD1 failed melanoma. The 140-patient study showed an overall response rate of 33.6%, meeting its primary endpoint, the company said. Price: 11.22,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved